Randomized Phase II Trials: Inevitable or Inadvisable?-Reference-Cited by-同舟云学术

Randomized Phase II Trials: Inevitable or Inadvisable?

Published:2010-05-20 Issue:15 Volume:28 Page:2641-2647
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Gan Hui K.¹,Grothey Axel¹,Pond Gregory R.¹,Moore Malcolm J.¹,Siu Lillian L.¹,Sargent Daniel¹

Affiliation:

1. From the Princess Margaret Hospital, Toronto; McMaster University, Hamilton, Ontario, Canada; and Mayo Clinic, Rochester, MN.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.26.3343

Reference45 articles.

1. Title 21: Food and Drugs; Chapter 1: Food and Drug Administration; Subchapter D: Drugs for Human Use 2007 US Food and Drug Administration Washington, DC Department of Health and Human Services, US Food and Drug Administration

2. The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” Decision

3. Economics of New Oncology Drug Development

4. The price of innovation: new estimates of drug development costs

5. Randomized Phase II Designs

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An evolutionary algorithm for the direct optimization of covariate balance between nonrandomized populations;Pharmaceutical Statistics;2023-12-18

2. Estimation of treatment effects in early-phase randomized clinical trials involving external control data;Journal of Biopharmaceutical Statistics;2023-10-12

3. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD;Trials;2023-09-15

4. Two-stage response adaptive randomization designs for multi-arm trials with binary outcome;Journal of Biopharmaceutical Statistics;2023-07-15

5. A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer;Frontiers in Oncology;2023-07-11